-transparent.png){kind=logo}
A patient was seen with absent pulses and vague symptoms. History and clinical findings supported a diagnosis of ergotism due to heavy use of ergotamine suppositories. The patient continued to use ergotamine despite warnings and was seen on two additional occasions with ergotism. Previously a heavy user of ergotamine, she became sensitive to small doses, demonstrating marked vasospasm after only one suppository. This phenomenon, not previously reported, is postulated secondarily to drug interaction. The patient is presented with a review of the pharmacology, toxicity, and treatment of ergotamine-induced ergotism. Alerted to the possibility of drug interactions, physicians may safely use ergotamine in the treatment of migraine headache with careful monitoring for signs and symptoms of early toxicity.
R W Curry, and
R R Yalamanchili
February 1965,
Radiology,
R W Curry, and
R R Yalamanchili
June 1998,
Angiology,
R W Curry, and
R R Yalamanchili
January 2005,
Revista de neurologia,
R W Curry, and
R R Yalamanchili
May 1969,
L'union medicale du Canada,
R W Curry, and
R R Yalamanchili
December 2016,
The International journal of angiology : official publication of the International College of Angiology, Inc,
R W Curry, and
R R Yalamanchili
December 2006,
Journal of clinical neurology (Seoul, Korea),
R W Curry, and
R R Yalamanchili
March 1998,
Annals of the Academy of Medicine, Singapore,
R W Curry, and
R R Yalamanchili
May 1978,
Revista clinica espanola,
R W Curry, and
R R Yalamanchili
March 1978,
Toxicological European research. Recherche europeenne en toxicologie,
